Sarepta Therapeutics, Inc. Share Price

Equities

SRPT

US8036071004

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 20:28:38 22/04/2024 BST 5-day change 1st Jan Change
117 USD +1.15% Intraday chart for Sarepta Therapeutics, Inc. -0.76% +21.76%
Sales 2024 * 1.8B 146B Sales 2025 * 2.9B 235B Capitalization 10.85B 878B
Net income 2024 * 189M 15.3B Net income 2025 * 997M 80.7B EV / Sales 2024 * 5.42 x
Net cash position 2024 * 1.07B 86.93B Net cash position 2025 * 2.58B 208B EV / Sales 2025 * 2.85 x
P/E ratio 2024 *
50.7 x
P/E ratio 2025 *
11.1 x
Employees 1,314
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.22%
More Fundamentals * Assessed data
Dynamic Chart
FDA greenlights Italfarmaco's drug for rare muscular dystrophy RE
Transcript : Sarepta Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:05 PM
Sarepta Therapeutics Insider Sold Shares Worth $1,848,795, According to a Recent SEC Filing MT
Transcript : Sarepta Therapeutics, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 10:00 AM
Sarepta Therapeutics Insider Sold Shares Worth $385,480, According to a Recent SEC Filing MT
UBS Raises Sarepta Therapeutics Price Target to $167 From $164, Maintains Buy Rating MT
Sarepta Therapeutics' Regulatory Drug Review Underpins Prospects for Rally, RBC Says MT
Deutsche Bank Cuts Sarepta Therapeutics Price Target to $156 From $158, Maintains Buy Rating MT
Needham Cuts Price Target on Sarepta Therapeutics to $166 From $169, Maintains Buy Rating MT
RBC Boosts Price Target on Sarepta Therapeutics to $157 From $151, Keeps Outperform Rating MT
Sarepta Therapeutics Swings to Q4 Profit, Revenue Increases; Shares Rise After Market MT
Transcript : Sarepta Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 Revenue $396.8M, vs. Street Est of $386.2M MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 EPS $0.82, vs. Street Est of $0.37 MT
Sarepta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
More news
1 day+1.17%
1 week-0.76%
Current month-9.31%
1 month-7.94%
3 months-3.01%
6 months+5.39%
Current year+21.76%
More quotes
1 week
114.37
Extreme 114.37
119.08
1 month
114.37
Extreme 114.37
131.16
Current year
91.34
Extreme 91.3439
143.00
1 year
55.25
Extreme 55.25
159.89
3 years
55.25
Extreme 55.25
159.89
5 years
55.25
Extreme 55.25
181.83
10 years
8.00
Extreme 8
181.83
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 25/06/17
Director of Finance/CFO 48 31/12/14
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 61 25/06/17
Chairman 71 30/03/09
Director/Board Member 65 01/06/15
More insiders
Date Price Change Volume
22/04/24 117.2 +1.41% 299 235
19/04/24 115.6 -0.80% 641,236
18/04/24 116.6 -1.14% 498,572
17/04/24 117.9 +0.51% 546,229
16/04/24 117.3 -0.86% 592,917

Delayed Quote Nasdaq, April 22, 2024 at 08:13 pm

More quotes
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
115.6 USD
Average target price
164.5 USD
Spread / Average Target
+42.31%
Consensus